Abstract | BACKGROUND: METHODS: A retrospective analysis was performed of patients undergoing liver transplantation due to HBV-induced liver disease at our center since 1988. A controlled HBIG discontinuation was conducted between 2015 and 2017 in 65 patients. Recurrent infection was determined by HbsAg values. Fibrosis and inflammation were evaluated by routine biopsy. The survival of patients after HBIG discontinuation was compared to a control population on HBIG for prophylaxis. RESULTS: From 1988 to 2013, 352 patients underwent liver transplantation due to HBV-induced liver disease. 169 patients could be included for analysis. 104 (51.5%) patients continued a prophylaxis containing HBIG. HBIG was discontinued in 65 (38.5%) patients in a controlled manner, maintaining an oral NUC. None of those patients showed HBV reinfection or graft dysfunction. No significant changes of inflammation grades (P = .067) or fibrosis stages (P = .051) were detected. The survival of patients after HBIG discontinuation was comparable to the control (P = .95). CONCLUSION:
HBIG withdrawal under continuation of oral NUC therapy is safe and not related to graft dysfunction, based on blood tests and histology. HBIG-free prophylaxis is not associated with a worse outcome and displays a financial relief as well as a logistic simplification during long-term follow-up.
|
Authors | Eva Maria Dobrindt, Eriselda Keshi, Yones Salim, Allan Gillespie, Akylbek Saipbaev, Wenzel Schöning, Robert Öllinger, Johann Pratschke, Dennis Eurich |
Journal | Transplant infectious disease : an official journal of the Transplantation Society
(Transpl Infect Dis)
Vol. 22
Issue 4
Pg. e13303
(Aug 2020)
ISSN: 1399-3062 [Electronic] Denmark |
PMID | 32367631
(Publication Type: Journal Article)
|
Copyright | © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Antiviral Agents
- Immunoglobulins
- hepatitis B hyperimmune globulin
|
Topics |
- Adolescent
- Adult
- Aged
- Antiviral Agents
(administration & dosage)
- Child
- Drug Administration Schedule
- Female
- Hepatitis B
(prevention & control, therapy)
- Hepatitis B, Chronic
(prevention & control, therapy)
- Humans
- Immunoglobulins
(administration & dosage)
- Liver Transplantation
(adverse effects)
- Male
- Medication Adherence
- Middle Aged
- Retrospective Studies
- Time Factors
- Withholding Treatment
- Young Adult
|